A research team has developed a new chemotherapeutic agent, LiPyDau, which shows remarkable efficacy against multiple tumor ...
NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum ...
Researchers have developed a groundbreaking new chemotherapeutic agent, LiPyDau, which shows remarkable efficacy against ...
SHELTON, CONNECTICUT / ACCESS Newswire / November 3, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs ...
News Medical on MSN
New chemotherapeutic agent shows remarkable efficacy against multiple tumor types
A research team led by the Medical University of Vienna, the HUN-REN Research Centre for Natural Sciences and the Eötvös Loránd University in Budapest has developed a groundbreaking new ...
Genprex, Inc. ("Genprex" or the "Company") , a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its ...
A nanovaccine uses tiny particles to encapsulate and deliver antigens to immune cells, triggering the body’s protective ...
12d
Hanmi Pharmaceutical Unveils Next-Generation Modalities, Debuts Innovative Targeted Anticancer Drug
Hanmi Pharmaceutical, the core business subsidiary of Hanmi Science, unveiled a range of next-generation modality research achievements at a ...
In a promising advance for cancer treatment, Northwestern University scientists have re-engineered the molecular structure of ...
Invited presentation followed by panel discussion on the next wave of innovation in immunotherapy of cancer: Paul Peter Tak, M.D., Ph.D., ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback